As of Nov 19, 2026, 1 of 2 active firms rate SUPN a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SUPN EPS & revenue forecast
EPS · NEXT QUARTER
$0.83
Range $0.81 – $0.86 · 2 analysts · -13% YoY
Next period, 2 analysts expect Supernus Pharmaceuticals Inc to earn $0.83 a share (range $0.81 – $0.86), versus $0.96 a year earlier. Full-year consensus is $3.69, growing to $4.00 the year after.
REVENUE · NEXT QUARTER
$578.0M
Range $561.3M – $594.6M · 2 analysts · +82% YoY
Revenue is expected to reach $578.0M (range $561.3M – $594.6M), +82.3% year-over-year. Full-year consensus is $2.3B, rising to $2.4B next year.
Top analysts covering Supernus Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SUPN.
#1
Chase Knickerbocker
Craig-Hallum · Rank #17
Buy
No targeton SUPN
Overall win rate
61%
+ Follow
#2
David Amsellem
Piper Sandler · Rank #124
Buy
$59.00+103.7% to target
Overall win rate
50%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$67.00+131.3% to target
Overall win rate
38%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$48.00+65.7% to target
Overall win rate
38%
+ Follow
#5
Annabel Samimy
Stifel
Neutral
$55.00+89.9% to target
Coverage
—
+ Follow
SUPN stock forecast FAQ
What is SUPN's average 12-month price target?+
The 2 active firms with a live target average $61.00 for Supernus Pharmaceuticals Inc over the next 12 months, ranging from a $67.00 high to a $55.00 low, as of Nov 19, 2026.
Is SUPN stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SUPN?+
The Street-high target is $67.00 (Cantor Fitzgerald), and the Street-low is $55.00 (Stifel). The average of all 2 active-firm targets is $61.00.
How many active Wall Street firms cover SUPN?+
2 active firms have a recognized rating on Supernus Pharmaceuticals Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SUPN?+
Among analysts who currently cover SUPN, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #17). Their current call is Buy.
What is Supernus Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.83 per share (range $0.81 – $0.86) across 2 analysts. Full-year EPS is projected at $3.69, rising to $4.00 the following year.
How much revenue is Supernus Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $578.0M (range $561.3M – $594.6M). Full-year revenue is projected at $2.3B, growing to $2.4B next year.
Have analysts been upgrading or downgrading SUPN lately?+
As of Nov 19, 2026, 1 of 2 active firms rate SUPN a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SUPN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.